These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29860884)

  • 1. [Atypical hemolytic uremic syndrome caused by primary complement defects].
    Reusz G
    Orv Hetil; 2018 Jun; 159(23):929-936. PubMed ID: 29860884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.
    Berger BE
    Am J Med Sci; 2016 Aug; 352(2):177-90. PubMed ID: 27524217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.
    Sridharan M; Go RS; Abraham RS; Fervenza FC; Sethi S; Bryant SC; Spears GM; Murray DL; Willrich MAV
    Mayo Clin Proc; 2018 Oct; 93(10):1351-1362. PubMed ID: 30286829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
    Richards A; Kavanagh D; Atkinson JP
    Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementopathies.
    Baines AC; Brodsky RA
    Blood Rev; 2017 Jul; 31(4):213-223. PubMed ID: 28215731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
    Westra D; Volokhina EB; van der Molen RG; van der Velden TJ; Jeronimus-Klaasen A; Goertz J; Gracchi V; Dorresteijn EM; Bouts AH; Keijzer-Veen MG; van Wijk JA; Bakker JA; Roos A; van den Heuvel LP; van de Kar NC
    Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Atypical Hemolytic Uremic Syndrome.
    Yoshida Y; Kato H; Ikeda Y; Nangaku M
    J Atheroscler Thromb; 2019 Feb; 26(2):99-110. PubMed ID: 30393246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of atypical hemolytic uremic syndrome (aHUS).
    Rodríguez de Córdoba S; Hidalgo MS; Pinto S; Tortajada A
    Semin Thromb Hemost; 2014 Jun; 40(4):422-30. PubMed ID: 24799305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient].
    Frémeaux-Bacchi V
    Biol Aujourdhui; 2013; 207(4):231-40. PubMed ID: 24594571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics and complement in atypical HUS.
    Kavanagh D; Goodship T
    Pediatr Nephrol; 2010 Dec; 25(12):2431-42. PubMed ID: 20526633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.
    Riedl M; Fakhouri F; Le Quintrec M; Noone DG; Jungraithmayr TC; Fremeaux-Bacchi V; Licht C
    Semin Thromb Hemost; 2014 Jun; 40(4):444-64. PubMed ID: 24911558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
    Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C
    Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.